Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686451 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18747143 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL14898381 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL13282208 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL19289866 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL13282112 | 0.95 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL19738597 | 0.88 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18789586 | 0.88 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL18426952 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTABCC4ACLY | |
| SCHEMBL21128960 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTABCC4ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| EP-3159352-B1 | STITCHED POLYPEPTIDES | HARVARD COLLEGE (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-10905739-B2 | Peptidomimetic macrocycles and formulations thereof | AILERON THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20100184645-A1 | STITCHED POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | ALDH1A1 4716/4885LMNA 3294/4885MAPT 905/4885 |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | ALDH1A1 4756/4885LMNA 3419/4885MAPT 2413/4885 |
| US-20100184645-A1 | STITCHED POLYPEPTIDES | VIP, IAPP, NGLY1 | ALDH1A1 4098/4885LMNA 3761/4885MAPT 2152/4885 |
| US-10905739-B2 | Peptidomimetic macrocycles and formulations thereof | MDM2, TP53, TP53BP1 | ALDH1A1 4716/4885LMNA 3294/4885MAPT 905/4885 |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | ILK, EPCAM, MMP8 | ALDH1A1 1432/4885LMNA 1494/4885MAPT 2159/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ALDH1A1 4843/4885LMNA 3985/4885MAPT 3661/4885 |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | WNT3A, CTNNBL1, WNT1 | ALDH1A1 4235/4885LMNA 1788/4885MAPT 4501/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | ALDH1A1 4459/4885LMNA 4476/4885MAPT 1935/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | ALDH1A1 4764/4885LMNA 2843/4885MAPT 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.